Form 4: ADMA Biologics CEO Adam Grossman Reports Changes in Beneficial Ownership
SEC Form 4 Filing
Adam Grossman, CEO of ADMA Biologics, reports the withholding of shares to cover tax obligations upon vesting of restricted stock units.
Summary
- On September 30, 2024, Adam Grossman, the President and CEO of ADMA Biologics, had 21,752 shares of common stock withheld by the issuer to satisfy mandatory tax withholding requirements upon the vesting of restricted stock units (RSUs) at a price of $19.99 per share.
- Following this transaction, Grossman directly owns 2,037,974 shares of ADMA Biologics common stock.
- Grossman also indirectly owns 1,143,426 shares through Areth, LLC, and 580,957 shares through Hariden, LLC.
Sentiment
Score: 5
Explanation: The document is a neutral regulatory filing detailing stock transactions. It doesn't inherently convey positive or negative sentiment.
Industry Context
This filing is a routine disclosure related to executive compensation and stock ownership, common in the biopharmaceutical industry.
Stakeholder Impact
- The transaction has a minor impact on shareholders as it involves the withholding of shares for tax purposes, which is a normal part of equity compensation.
Key Dates
| Date | Description |
|---|---|
| 09/30/2024 | Date of transaction: Shares withheld for tax obligations upon vesting of restricted stock units. |
| 10/02/2024 | Date of signature for the Form 4 filing. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.